维普中文期刊产品整合服务
174篇 您的检索式:作者名="Butt F"
    题名 作者 年代 出处 被引量
1Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage显示文摘AIM: To evaluate pegylated interferon alpha2a (PegIFN- α2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate. METHODS: A total of 73 na?ve patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed. RESULTS: Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-α2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response betweenbilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable. CONCLUSION: PegIFN-α2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation.MF Derbala SR Al Kaabi NZ El Dweik F Pasic MT Butt R Yakoob A Al-Marri AM Amer N Morad A Bener 2006World Journal of Gastroenterology2006,12,35:3
2Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study 显示文摘Kumarasamy KK Toleman MA Walsh TR Bagaria J Butt F Balakrishnan R Chaudhary U Doumith M Giske CG Irfan S Krishnan P Kumar AV Maharjan S Mushtaq S Noorie T Paterson DL Pearson A Perry C Pike R Rao B Ray U Sarma JB Sharma M Sheridan E Thirunarayan MA Turton J Upadhyay S Warner M Welfare W Livermore DM Woodford N 2010Lancet Infect Dis2010,10,9:1
3Safety assessment of black cumin fixed and essential oil in normal Sprague Dawley rats: serological and hematological indices显示文摘TAUSEEF S M BUTT M S ANJUM F M 2009Food and Chemistry Toxicology2009,47,:1
4Comparison between prostaglandin E1 and epoprostenol (prostacyclin) in infants after heart surgery 显示文摘Kermode J Butt W Shann F 1991Br Heart J1991,66,:1
5Pattern of head and neck malignant neoplasms in HIV-infecled pa tients in Kenya显示文摘Butt FM Chindia ML Rana F 2008Int J Oral Maxillofac Surg2008,37,10:1
6Pattern of head and neck malignant neoplasms in HIV-infected patients in Kenya显示文摘Butt FM Chindia ML Rana F 2008Int J Oral Maxillofac Surg2008,37,10:1
7Overview transient liquid phase bonding 显示文摘Gale W F Butts D A 2004Science and Technology of Welding and Joining2004,9,4:1
8A pilot study assessing the prognostic value of CK18 and n DNA biomarkers in severe sepsis patients显示文摘Moore DJ Greystoke A Butt F 2012Clin Drug Investig2012,32,3:1
9Characteriszation of foulants by autopsy of RO desalination membranes显示文摘Butt F H Rahman F Badumthamal U 1997Desalination1997,114,:1
10Upper cervical and upper thoracic manipulation versus mobilization and exercise in patients with cervicogenic headache:a multi - center randomized clinical trial 显示文摘Dunning JR Butts R Mourad F 2016BMC Musculoskelet Disord2016,17,1:1
11An intematioinal, multicenter, randomized phase III study of firstline erlotinib followed by second - line cisplatin/gemcitabine versus firstline cisplatin/gemcitabine followed by second - line erlotinib in advanced non - small - cell lung cancer: Treatment rationale and protocol dynamics of the TORCH trial 显示文摘Gridelli C Butts C Ciardiello F 2008Clin Lung Cancer2008,9,4:1
12查看详情显示文摘Feltin E Carlin J F Dorsaz J Christmann G Butte R Latigt M Ilegems M Grandjean N 0,,:1
13Evaluation of SHMP and advanced scale inhibitor for control of CaSO4,SrSO4 and CaCO3 scales in RO desalination显示文摘F H Butt F Rahman U Baduruthamal 1997Desalination1997,109,3:1
14Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance显示文摘Sun Y Butte N F Garcia J M 2008Endocrinology2008,149,2:1
15TNF-alpha: a risk fac- tor for ischemic stroke 显示文摘Bokhari FA1 Shakoori TA Butt A Ghafoor F 2014J Ayub Med Coil Abbottabad2014,26,2:1
16Rice Bran: A Novel Functional Ingredient 显示文摘Sharif M K Butt M S Anjum F M 2014Critical reviews in food science and nutrition2014,54,6:1
17Numerical model of impact-damped continuous systems 显示文摘Butt A S Akl F A 1997Journal of Engineering Mechanics1997,,:1
18An international multicenter, randomized phase Ⅲ study of first line erlotinib followed by second line cisplatin/gcmcitabine versus first line cisplatin/gemcitabine followed by second line erlotinib in ad vanced non small cell lung cancer; treatment rationale and protocol dynamics of the TORCH trial显示文摘Gridelli C Butts C Ciardiello F 2008Clin Lung Canc- er2008,9,4:1
19Numerical model of impact-damped continu-ous systems显示文摘Butt A S Akl F A 1997Journal of Engineering Mechanics1997,123,4:1
20De velopment of predictive models for end use quality of springwheat's through canonical analysis显示文摘Butt M S Anjum F M van Zuilichem D J Shaheen M 2001International Journal of Food Science and Technology2001,36,:1
返回顶部 每页显示:
共9页 首页 上一页 第1页 下一页 末页 /9 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费